September 2014: NSAWW is pleased to welcome Sigma-Tau Pharmaceuticals, a leading research-based pharmaceutical company with a worldwide presence, as its newest client in the Global Health and Wellness practice. Sigma-Tau focuses its research and development efforts mainly on cardiovascular disease, metabolism, oncology, immunology, and the central and peripheral nervous systems, with an emphasis on creating novel treatments for patients with rare diseases. NSAWW has been successfully expanding in the commercial market and the joining of Sigma-Tau Pharmaceuticals to our client roster underscores our continued commitment to growth in the commercial health arena. Courtney Spaeth, CEO of NSAWW, states that “The addition of Sigma-Tau Pharmaceuticals as a client represents the firm’s commitment to further support the transformational efforts of the healthcare industry worldwide.” NSAWW will deliver strategic consulting services to Sigma-Tau Pharmaceutical.